Recruiting PHASE1 NCT07321626
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
Efficacy and Safety of Romiplostim N01 in Promoting Platelet Reconstruction After Haploidentical Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies
Sponsor: First Affiliated Hospital of Zhejiang University
Interventions
Romiplostim N01 Standard Supportive Care
Updated 1 time since 2026 Last updated: Jan 26, 2026 Started: Jun 1, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027
This PHASE1 trial investigates Acute Myeloid Leukemia and Delayed Platelet Engraftment and is currently actively recruiting participants. First Affiliated Hospital of Zhejiang University leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- First Affiliated Hospital of Zhejiang University
Data source: First Affiliated Hospital of Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .